Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers
We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign ( n =51), malignant ( n =87), and borderline ( n =53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100...
Gespeichert in:
| Veröffentlicht in: | Bulletin of experimental biology and medicine 2016-03, Vol.160 (5), p.698-701 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 701 |
|---|---|
| container_issue | 5 |
| container_start_page | 698 |
| container_title | Bulletin of experimental biology and medicine |
| container_volume | 160 |
| creator | Abrosimov, A. Yu Dvinskikh, N. Yu Sidorin, A. V. |
| description | We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign (
n
=51), malignant (
n
=87), and borderline (
n
=53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100%). Follow up over 1-10 years after surgical treatment for borderline tumors showed no progression of tumor growth. We conclude that some benign and borderline tumors represent low-grade neoplasms with favorable prognosis. |
| doi_str_mv | 10.1007/s10517-016-3253-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1779889571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A455404995</galeid><sourcerecordid>A455404995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-4b13d5a78dac1196c1519bb684083110307976430303e78c833f2877aa2ae7513</originalsourceid><addsrcrecordid>eNp1kUFv1DAUhC0EarelP4ALioSEuKT42XHsHNtVKUitelnOltd52XVJ7MVOpO6_x9G20CKQD362vxl5NIS8A3oOlMrPCagAWVKoS84EL-EVWYCQvFSMwWuyoBkqK6XUMTlJ6X4-0hqOyDGTlPFssSDXS-z7VISuuETvNr4wvi0uQ2wx9s5jsdruY3BtsZqGEIurh13ElIpb02fWeLvPY_yBMb0lbzrTJzx73E_J9y9Xq-XX8ubu-tvy4qa0laRjWa2Bt8JI1RoL0NQWBDTrda0qqjgA5VQ2sq54HjhKZRXnHVNSGsMMSgH8lHw6-O5i-DlhGvXgks0ZjMcwJQ1SNko1Qs7oh7_Q-zBFn3-nQdVUNYzW6g-1MT1q57swRmNnU31RCVHRqmlEps7_QeXV4uBs8Ni5fP9C8PGZYIumH7cp9NPogk8vQTiANoaUInZ6F91g4l4D1XPL-tCyzi3ruWU9J3v_mGxaD9j-VjzVmgF2AFJ-8huMz6L_1_UX1WSsJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1860892068</pqid></control><display><type>article</type><title>Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Abrosimov, A. Yu ; Dvinskikh, N. Yu ; Sidorin, A. V.</creator><creatorcontrib>Abrosimov, A. Yu ; Dvinskikh, N. Yu ; Sidorin, A. V.</creatorcontrib><description>We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign (
n
=51), malignant (
n
=87), and borderline (
n
=53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100%). Follow up over 1-10 years after surgical treatment for borderline tumors showed no progression of tumor growth. We conclude that some benign and borderline tumors represent low-grade neoplasms with favorable prognosis.</description><identifier>ISSN: 0007-4888</identifier><identifier>EISSN: 1573-8221</identifier><identifier>DOI: 10.1007/s10517-016-3253-1</identifier><identifier>PMID: 27023100</identifier><identifier>CODEN: BEXBAN</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Biomarkers, Tumor - biosynthesis ; Biomedical and Life Sciences ; Biomedicine ; Cell Biology ; Cyclin D1 - biosynthesis ; Development and progression ; Diagnosis ; Female ; Fibronectins ; Fibronectins - biosynthesis ; Galectin 3 - biosynthesis ; Humans ; Immunohistochemistry ; Internal Medicine ; Keratin ; Keratin-19 - biosynthesis ; Laboratory Medicine ; Male ; Pathology ; Thyroid diseases ; Thyroid Gland - pathology ; Thyroid Gland - surgery ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - surgery ; Tumors ; Young Adult</subject><ispartof>Bulletin of experimental biology and medicine, 2016-03, Vol.160 (5), p.698-701</ispartof><rights>Springer Science+Business Media New York 2016</rights><rights>COPYRIGHT 2016 Springer</rights><rights>Bulletin of Experimental Biology and Medicine is a copyright of Springer, 2016.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-4b13d5a78dac1196c1519bb684083110307976430303e78c833f2877aa2ae7513</citedby><cites>FETCH-LOGICAL-c470t-4b13d5a78dac1196c1519bb684083110307976430303e78c833f2877aa2ae7513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10517-016-3253-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10517-016-3253-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27023100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abrosimov, A. Yu</creatorcontrib><creatorcontrib>Dvinskikh, N. Yu</creatorcontrib><creatorcontrib>Sidorin, A. V.</creatorcontrib><title>Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers</title><title>Bulletin of experimental biology and medicine</title><addtitle>Bull Exp Biol Med</addtitle><addtitle>Bull Exp Biol Med</addtitle><description>We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign (
n
=51), malignant (
n
=87), and borderline (
n
=53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100%). Follow up over 1-10 years after surgical treatment for borderline tumors showed no progression of tumor growth. We conclude that some benign and borderline tumors represent low-grade neoplasms with favorable prognosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Biology</subject><subject>Cyclin D1 - biosynthesis</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Fibronectins</subject><subject>Fibronectins - biosynthesis</subject><subject>Galectin 3 - biosynthesis</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Internal Medicine</subject><subject>Keratin</subject><subject>Keratin-19 - biosynthesis</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Pathology</subject><subject>Thyroid diseases</subject><subject>Thyroid Gland - pathology</subject><subject>Thyroid Gland - surgery</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - surgery</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0007-4888</issn><issn>1573-8221</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUFv1DAUhC0EarelP4ALioSEuKT42XHsHNtVKUitelnOltd52XVJ7MVOpO6_x9G20CKQD362vxl5NIS8A3oOlMrPCagAWVKoS84EL-EVWYCQvFSMwWuyoBkqK6XUMTlJ6X4-0hqOyDGTlPFssSDXS-z7VISuuETvNr4wvi0uQ2wx9s5jsdruY3BtsZqGEIurh13ElIpb02fWeLvPY_yBMb0lbzrTJzx73E_J9y9Xq-XX8ubu-tvy4qa0laRjWa2Bt8JI1RoL0NQWBDTrda0qqjgA5VQ2sq54HjhKZRXnHVNSGsMMSgH8lHw6-O5i-DlhGvXgks0ZjMcwJQ1SNko1Qs7oh7_Q-zBFn3-nQdVUNYzW6g-1MT1q57swRmNnU31RCVHRqmlEps7_QeXV4uBs8Ni5fP9C8PGZYIumH7cp9NPogk8vQTiANoaUInZ6F91g4l4D1XPL-tCyzi3ruWU9J3v_mGxaD9j-VjzVmgF2AFJ-8huMz6L_1_UX1WSsJA</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Abrosimov, A. Yu</creator><creator>Dvinskikh, N. Yu</creator><creator>Sidorin, A. V.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers</title><author>Abrosimov, A. Yu ; Dvinskikh, N. Yu ; Sidorin, A. V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-4b13d5a78dac1196c1519bb684083110307976430303e78c833f2877aa2ae7513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Biology</topic><topic>Cyclin D1 - biosynthesis</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Fibronectins</topic><topic>Fibronectins - biosynthesis</topic><topic>Galectin 3 - biosynthesis</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Internal Medicine</topic><topic>Keratin</topic><topic>Keratin-19 - biosynthesis</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Pathology</topic><topic>Thyroid diseases</topic><topic>Thyroid Gland - pathology</topic><topic>Thyroid Gland - surgery</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - surgery</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abrosimov, A. Yu</creatorcontrib><creatorcontrib>Dvinskikh, N. Yu</creatorcontrib><creatorcontrib>Sidorin, A. V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bulletin of experimental biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abrosimov, A. Yu</au><au>Dvinskikh, N. Yu</au><au>Sidorin, A. V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers</atitle><jtitle>Bulletin of experimental biology and medicine</jtitle><stitle>Bull Exp Biol Med</stitle><addtitle>Bull Exp Biol Med</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>160</volume><issue>5</issue><spage>698</spage><epage>701</epage><pages>698-701</pages><issn>0007-4888</issn><eissn>1573-8221</eissn><coden>BEXBAN</coden><abstract>We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign (
n
=51), malignant (
n
=87), and borderline (
n
=53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100%). Follow up over 1-10 years after surgical treatment for borderline tumors showed no progression of tumor growth. We conclude that some benign and borderline tumors represent low-grade neoplasms with favorable prognosis.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27023100</pmid><doi>10.1007/s10517-016-3253-1</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-4888 |
| ispartof | Bulletin of experimental biology and medicine, 2016-03, Vol.160 (5), p.698-701 |
| issn | 0007-4888 1573-8221 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1779889571 |
| source | MEDLINE; Springer Online Journals |
| subjects | Adolescent Adult Biomarkers, Tumor - biosynthesis Biomedical and Life Sciences Biomedicine Cell Biology Cyclin D1 - biosynthesis Development and progression Diagnosis Female Fibronectins Fibronectins - biosynthesis Galectin 3 - biosynthesis Humans Immunohistochemistry Internal Medicine Keratin Keratin-19 - biosynthesis Laboratory Medicine Male Pathology Thyroid diseases Thyroid Gland - pathology Thyroid Gland - surgery Thyroid Neoplasms - pathology Thyroid Neoplasms - surgery Tumors Young Adult |
| title | Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A15%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cells%20of%20Benign%20and%20Borderline%20Thyroid%20Tumor%20Express%20Malignancy%20Markers&rft.jtitle=Bulletin%20of%20experimental%20biology%20and%20medicine&rft.au=Abrosimov,%20A.%20Yu&rft.date=2016-03-01&rft.volume=160&rft.issue=5&rft.spage=698&rft.epage=701&rft.pages=698-701&rft.issn=0007-4888&rft.eissn=1573-8221&rft.coden=BEXBAN&rft_id=info:doi/10.1007/s10517-016-3253-1&rft_dat=%3Cgale_proqu%3EA455404995%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1860892068&rft_id=info:pmid/27023100&rft_galeid=A455404995&rfr_iscdi=true |